MUST Competitive Renewal

必须有竞争力的更新

• 批准号: 8849445
• 负责人: MICHAEL M ALTAWEEL
• 金额: $ 21.24万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-15 至 2016-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8849445
• 关键词: Adrenal Cortex Hormones; Adverse effects; Angiography; Autoimmune Process; Blindness; Cataract; Characteristics; Choroidal Neovascularization; Chronic; Chronic Disease; Clinical; Clinical Management; Clinical Research; Clinical Trials; Clinical Trials Network; Collaborations; Color; Data; Development; Disease; Effectiveness; Epidemiologic Studies; Epiretinal Membrane; Evaluation; Eye diseases; FDA approved; Feedback; Fluocinolone Acetonide; Fluorescein; Fluorescein Angiography; Funding; Fundus; Fundus photography; Glaucoma; Goals; Group Structure; Humira; Image; Image Analysis; Imaging Techniques; Immunosuppression; Immunosuppressive Agents; Implant; Inflammation; Inflammatory; Instruction; Laboratories; Leadership; Local Therapy; Lucentis; Modality; Monitor; Monoclonal Antibodies; Morbidity - disease rate; Optical Coherence Tomography; Oral; Outcome; Outcomes Research; Panuveitis; Patient Agents; Patients; Pharmaceutical Preparations; Pharmacotherapy; Phase; Pilot Projects; Preparation; Procedures; Process; Protocols documentation; Publications; Randomized Controlled Clinical Trials; Reaction; Reading; Relative (related person); Reporting; Research; Research Personnel; Resources; Retinal; Retinal Neovascularization; Safety; San Francisco; Scanning; Series; Severities; Steroids; Systemic Therapy; Training; Triamcinolone; Triamcinolone Acetonide; Tumor Necrosis Factor-alpha; United States; Universities; Uveitis; Vascular Diseases; Vascular Endothelial Growth Factors; Vision; Visual; Visual impairment; Wisconsin; adalimumab; age related; cohort; comparative efficacy; comparative trial; compare effectiveness; design; effective therapy; evidence base; follow-up; high risk; human monoclonal antibodies; improved; inhibitor/antagonist; lens; macular edema; novel; randomized trial; ranibizumab; research study; standard care; stereoscopic; therapy design; treatment trial; trial comparing; young adult

Intermediate, posterior, and panuveitis are major causes of vision loss and blindness in the United States. With a peak onset in young adulthood, vision loss due to uveitis will have a greater impact on years of potential vision lost per case than age-related eye diseases. Most of these diseases are chronic and require long-term treatment. Current therapy typically involves the use of oral corticosteroids, supplemented by immunosuppressive drugs in selected situations. The NEI funded MUST trial is comparing the efficacy and morbidity associated with the use of fluocinolone acetonide intraocular implant versus standard therapy with systemic corticosteroids and immunosuppressive medications for such patients. Valuable data being gathered will influence treatment choices. The MUST 2 trial will follow this group for another 6 years, providing objective information regarding the long-term visual and morphologic effects of severe uveitis and further guidance regarding the best management for a chronic disorder. Adalimumab, a TNF inhibitor that downregulates the inflammatory reaction in inflammatory diseases, provides a novel and potentially effective approach to managing uveitis. One protocol will compare the efficacy and morbidity (ocular and systemic) of adalimumab versus corticosteroids and standard immunosuppression for severe uveitis. A common cause of vision loss in uveitis is the development of macular edema. Modalities of treatment found effective for retinal vascular disease have been applied to management of uveitis-related macular edema but do not have sufficient evidence to support their continued use or longterm data regarding safety. Two trials would evaluate the efficacy and safety of intravitreal triamcinolone (Triessence) versus standard subtenons triamcinolone, and intravitreal ranibizumab versus intravitreal triamcinolone for uveitic macular edema. These would be the first randomized trials to properly direct our further management of this common clinical entity. This application supports the creation of a study network that includes a Reading center capable of objectively assessing morphologic ocular changes due to uveitis and it's complications. This resource center will participate in the design, conduct, analysis and reporting of the network studies.

中间葡萄膜炎、后葡萄膜炎和全葡萄膜炎是美国视力丧失和失明的主要原因。 由于葡萄膜炎导致的视力丧失在成年早期发病高峰，将对以后数年产生更大的影响。 与年龄相关的眼病相比，每例潜在的视力损失。这些疾病大多数是慢性的，需要 长期治疗。目前的治疗通常包括使用口服皮质类固醇，辅以 在特定情况下使用免疫抑制药物。 NEI 资助的 MUST 试验正在比较疗效和 与使用氟轻松眼内植入物与标准治疗相关的发病率 对此类患者进行全身性皮质类固醇和免疫抑制药物治疗。有价值的数据有 收集的信息将影响治疗选择。 MUST 2 试验将继续跟踪该组 6 年， 提供有关严重葡萄膜炎的长期视觉和形态影响的客观信息 关于慢性病最佳治疗的进一步指导。阿达木单抗，一种 TNF 抑制剂 下调炎症性疾病中的炎症反应，提供了一种新颖且潜在有效的治疗方法 治疗葡萄膜炎的方法。一项方案将比较以下药物的疗效和发病率（眼部和全身） 阿达木单抗与皮质类固醇和标准免疫抑制治疗严重葡萄膜炎的比较。一个常见的原因是 葡萄膜炎导致的视力丧失是黄斑水肿的发展。发现对视网膜有效的治疗方式 血管疾病已应用于葡萄膜炎相关黄斑水肿的治疗，但尚未 有足够的证据支持其继续使用或有关安全性的长期数据。两次试验将 评估玻璃体内注射曲安西龙 (Triessence) 与标准眼球筋膜下注射的疗效和安全性 曲安西龙和玻璃体内注射雷珠单抗与玻璃体内注射曲安西龙治疗葡萄膜炎性黄斑水肿。 这些将是第一个随机试验，以正确指导我们对这种常见临床的进一步管理 实体。该应用程序支持创建一个学习网络，其中包括一个能够 客观评估葡萄膜炎及其并发症引起的眼部形态变化。这个资源中心 将参与网络研究的设计、实施、分析和报告。

项目成果

Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.

• DOI: 10.1016/j.ophtha.2014.04.022
• 发表时间: 2014-10
• 期刊: OPHTHALMOLOGY
• 影响因子: 13.7
• 作者: Sugar, Elizabeth A.;Holbrook, Janet T.;Kempen, John H.;Burke, Alyce E.;Drye, Lea T.;Thorne, Jennifer E.;Louis, Thomas A.;Jabs, Douglas A.;Altaweel, Michael M.;Frick, Kevin D.
• 通讯作者: Frick, Kevin D.

Cataract Surgery Outcomes in Uveitis: The Multicenter Uveitis Steroid Treatment Trial.

• DOI: 10.1016/j.ophtha.2015.09.022
• 发表时间: 2016-01
• 期刊: Ophthalmology
• 影响因子: 13.7
• 作者: Sen HN;Abreu FM;Louis TA;Sugar EA;Altaweel MM;Elner SG;Holbrook JT;Jabs DA;Kim RY;Kempen JH;Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group
• 通讯作者: Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group

Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema.

• DOI: 10.1016/j.ophtha.2013.01.069
• 发表时间: 2013-09
• 期刊: Ophthalmology
• 影响因子: 13.7
• 作者: Kempen JH;Sugar EA;Jaffe GJ;Acharya NR;Dunn JP;Elner SG;Lightman SL;Thorne JE;Vitale AT;Altaweel MM;Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group
• 通讯作者: Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group

Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial.

• DOI: 10.1016/j.ophtha.2013.01.025
• 发表时间: 2013-08
• 期刊: Ophthalmology
• 影响因子: 13.7
• 作者: Friedman DS;Holbrook JT;Ansari H;Alexander J;Burke A;Reed SB;Katz J;Thorne JE;Lightman SL;Kempen JH;MUST Research Group
• 通讯作者: MUST Research Group

Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography.

• DOI: 10.1016/j.ajo.2011.05.028
• 发表时间: 2011-12
• 期刊: AMERICAN JOURNAL OF OPHTHALMOLOGY
• 影响因子: 4.2
• 作者: Sugar, Elizabeth A.;Jabs, Douglas A.;Altaweel, Michael M.;Lightman, Sue;Acharya, Nisha;Vitale, Albert T.;Thorne, Jennifer E.
• 通讯作者: Thorne, Jennifer E.